Trial Summary
What is the purpose of this trial?The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.
Eligibility Criteria
This trial is for adults listed for liver transplantation who can give informed consent and follow the study procedures. It's not for those with a BMI over 40, recent investigational drug/device use, multiple biliary anastomoses planned, non-liver cancers, uncontrolled infections, or expecting to receive a deceased donor liver transplant.Inclusion Criteria
I am on the liver transplant list.
I am mentally capable of understanding and signing the consent form.
My gender does not affect my eligibility for this study.
+3 more
Exclusion Criteria
I am scheduled for surgery on my pancreas or stomach.
Body mass index > 40
Treatment with any investigational drug/device within 60 days prior to study entry
+7 more
Participant Groups
The study tests the safety of using one's own fat-derived stem cells (AMSC) in patients with end-stage liver disease during live donor liver transplants to prevent bile duct complications.
1Treatment groups
Experimental Treatment
Group I: Liver TransplantExperimental Treatment1 Intervention
Subjects with liver disease with planned living donor liver transplantation
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Mayo Clinic in RochesterRochester, MN
Loading ...
Who Is Running the Clinical Trial?
Mayo ClinicLead Sponsor